GlaxoSmithKline: Infections trials

The registry lists 163 Infections studies with GlaxoSmithKline as lead sponsor. 1 are open to participants now and 57 have results posted.

Phase 1 85Phase 2 29Phase 3 27Phase 4 10No phase 13(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIVAvailableNCT03462810
• A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy AdultsCompletedNCT05966090Phase 3Results posted
• A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of AgeCompletedNCT05496231Phase 1/2Results posted
• A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy InfantsCompletedNCT05412030Phase 2Results posted
• Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy AdultsCompletedNCT04425902Phase 1Results posted
• Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)CompletedNCT03368053Phase 1Results posted
• A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without RitonavirCompletedNCT03234036Phase 1Results posted
• GSK3640254 First Time in Human (FTIH) Study in Healthy VolunteersCompletedNCT03231943Phase 1Results posted
• Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy SubjectsCompletedNCT03149848Phase 1Results posted
• Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and LamivudineCompletedNCT03078556Phase 1Results posted
• Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected AdultsCompletedNCT03045861Phase 2Results posted
• Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsActive, not recruitingNCT02951052Phase 3Results posted
• An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)CompletedNCT02831764Phase 3Results posted
• An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)CompletedNCT02831673Phase 3Results posted
• A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy VolunteersCompletedNCT02634073Phase 4Results posted
• Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult VolunteersCompletedNCT02478463Phase 1Results posted
• Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive AdultsTerminatedNCT02415595Phase 2Results posted
• Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infectionCompletedNCT02178592Phase 3Results posted
• AUGMENTIN™ in Dental InfectionsCompletedNCT02141217Phase 4Results posted
• A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult SubjectsCompletedNCT02120352Phase 2Results posted
• A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral RegimenCompletedNCT02105987Phase 3Results posted
• Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)CompletedNCT02076178Phase 2Results posted
• ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus InfectionCompletedNCT02075593Phase 3Results posted
• Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT02045797Phase 2Results posted
• Study to Assess the Efficacy and Safety of Potassium Clavulanate/Amoxicillin in Children With Acute Bacterial RhinosinusitisCompletedNCT01934231Phase 3Results posted
• A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)CompletedNCT01910402Phase 3Results posted
• Study to Evaluate a HIV Drug for the Treatment of HIV InfectionCompletedNCT01803074Phase 2Results posted
• Dose Ranging of GSK2336805 in Combination TherapyCompletedNCT01648140Phase 2Results posted
• Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus RilpivirineCompletedNCT01641809Phase 2Results posted
• A Study of Belimumab in the Prevention of Kidney Transplant RejectionCompletedNCT01536379Phase 2Results posted
• A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive SubjectsCompletedNCT01499199Phase 3Results posted
• Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive SubjectsCompletedNCT01449929Phase 3Results posted
• HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) InfectionsCompletedNCT01384734Phase 2Results posted
• GSK2251052 in the Treatment of Complicated Intra-abdominal InfectionsTerminatedNCT01381562Phase 2Results posted
• A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.CompletedNCT01328041Phase 3Results posted
• A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)CompletedNCT01263015Phase 3Results posted
• Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)TerminatedNCT01231555Phase 2Results posted
• A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive AdultsCompletedNCT01231516Phase 3Results posted
• A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice DailyCompletedNCT01227824Phase 3Results posted
• Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV InfectionTerminatedNCT01199731Phase 2Results posted
• A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)CompletedNCT01102972Phase 4Results posted
• Fosamprenavir in Pts With Hepatic ImpairmentCompletedNCT01054586Results posted
• A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive SubjectsCompletedNCT00951015Phase 2Results posted
• A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to RaltegravirCompletedNCT00950859Phase 2Results posted
• Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.CompletedNCT00945282Phase 2Results posted
• Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)CompletedNCT00920426Phase 2Results posted
• Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected AdultsCompletedNCT00708110Phase 2Results posted
• Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)CompletedNCT00684177Phase 3Results posted
• Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.CompletedNCT00555061Phase 4Results posted
• KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive SubjectsCompletedNCT00549198Phase 4Results posted
• Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.CompletedNCT00481767Phase 3Results posted
• HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive AdultsCompletedNCT00450580Phase 3Results posted
• Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 InfectionCompletedNCT00440947Phase 3Results posted
• A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected SubjectsCompletedNCT00363142Phase 3Results posted
• A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected SubjectsCompletedNCT00296504Phase 3Results posted
• Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected SubjectsTerminatedNCT00197145Phase 3Results posted
• 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV InfectionCompletedNCT00089583Phase 2Results posted
• Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric SubjectsCompletedNCT00071760Phase 2Results posted
• A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and AboveCompletedNCT07204964Phase 2
• A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and OlderCompletedNCT07121192Phase 2
• PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)CompletedNCT03327740
• Phase 4 Study of Dolutegravir (DTG) in Russian FederationCompletedNCT03314064Phase 4
• Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex With MenCompletedNCT03310515
• Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible TabletCompletedNCT02893488Phase 1
• A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy SubjectsCompletedNCT02859259Phase 1
• Absolute Bioavailability of BMS-626529 After Oral and Intravenous DosingCompletedNCT02805556Phase 1
• A Study to Evaluate the Effect of High Fat Meal on CabotegravirCompletedNCT02799264Phase 1
• Single and Repeated Dose Escalation Study of GSK2838232CompletedNCT02795754Phase 1
• Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)CompletedNCT02741557Phase 1
• Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose CombinationsCompletedNCT02738931Phase 1
• A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176CompletedNCT02715479Phase 1
• A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy SubjectsCompletedNCT02666053Phase 1
• A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/NaloxoneCompletedNCT02666001Phase 1
• A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy SubjectsTerminatedNCT02576119Phase 1
• Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese SubjectsCompletedNCT02539576Phase 1
• Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release TabletCompletedNCT02508064Phase 1
• A Open-label, Drug-Drug Interaction With Maraviroc (DDI)CompletedNCT02480894Phase 1
• A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)CompletedNCT02480881Phase 1
• Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy SubjectsCompletedNCT02467335Phase 1
• Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy SubjectsCompletedNCT02411435Phase 1
• Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy SubjectsCompletedNCT02373930Phase 1
• Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal ImpairmentCompletedNCT02354937Phase 1
• Relative Bioavailability Study of Phase III Tablet Formulation of CabotegravirCompletedNCT02345707Phase 1
• A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy SubjectsTerminatedNCT02289495Phase 1
• A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy SubjectsTerminatedNCT02289482Phase 1
• A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)CompletedNCT02277600Phase 1
• Food Effect Study With BMS-955176CompletedNCT02273947Phase 1
• Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy VolunteersCompletedNCT02185300Phase 1
• Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529CompletedNCT02164045Phase 1
• Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female SubjectsCompletedNCT02159131Phase 1
• Study of Combined Oral Contraceptive Effects in Female SubjectsCompletedNCT02157467Phase 1
• Drug-drug Interaction (DDI) RifabutinCompletedNCT02138084Phase 1
• Relative Bioavailability Study With BMS-955176CompletedNCT02095886Phase 1
• Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult SubjectsCompletedNCT02082808Phase 1
• A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in GermanyCompletedNCT02076386
• Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult SubjectsCompletedNCT02064374Phase 1
• DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)CompletedNCT02063360Phase 1
• A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult SubjectsCompletedNCT02059031Phase 1
• Study to Evaluate the Effect of GSK1265744 on Cardiac ConductionCompletedNCT02027454Phase 1
• Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis.TerminatedNCT02000453Phase 1